Mechanisms for the transition from physiological to pathological cardiac hypertrophy

被引:134
|
作者
Oldfield, Christopher J. [1 ,2 ]
Duhamel, Todd A. [1 ,2 ]
Dhalla, Naranjan S. [2 ,3 ]
机构
[1] Univ Manitoba, Fac Kinesiol & Recreat Management, Winnipeg, MB R3T 2N2, Canada
[2] St Boniface Gen Hosp, Inst Cardiovasc Sci, Albrechtsen Res Ctr, Winnipeg, MB R2H 2A6, Canada
[3] Univ Manitoba, Max Rady Coll Med, Dept Physiol & Pathophysiol, Winnipeg, MB R3E 0J9, Canada
关键词
cardiac hypertrophy; cardiac remodeling; pathological cardiac hypertrophy; physiological cardiac hypertrophy; adaptive cardiac hypertrophy; cardiac contractile function; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; PRESSURE-OVERLOAD HYPERTROPHY; RETICULUM GENE-EXPRESSION; OXIDATIVE STRESS; HEART-FAILURE; SARCOPLASMIC-RETICULUM; ANGIOTENSIN-II; FACTOR-BETA; DIASTOLIC DYSFUNCTION;
D O I
10.1139/cjpp-2019-0566
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The heart is capable of responding to stressful situations by increasing muscle mass, which is broadly defined as cardiac hypertrophy. This phenomenon minimizes ventricular wall stress for the heart undergoing a greater than normal workload. At initial stages, cardiac hypertrophy is associated with normal or enhanced cardiac function and is considered to be adaptive or physiological; however, at later stages, if the stimulus is not removed, it is associated with contractile dysfunction and is termed as pathological cardiac hypertrophy. It is during physiological cardiac hypertrophy where the function of subcellular organelles, including the sarcolemma, sarcoplasmic reticulum, mitochondria, and myofibrils, may be upregulated, while pathological cardiac hypertrophy is associated with downregulation of these subcellular activities. The transition of physiological cardiac hypertrophy to pathological cardiac hypertrophy may be due to the reduction in blood supply to hypertrophied myocardium as a consequence of reduced capillary density. Oxidative stress, inflammatory processes, Ca2+-handling abnormalities, and apoptosis in cardiomyocytes are suggested to play a critical role in the depression of contractile function during the development of pathological hypertrophy.
引用
收藏
页码:74 / 84
页数:11
相关论文
共 50 条
  • [1] Mechanisms of physiological and pathological cardiac hypertrophy
    Nakamura, Michinari
    Sadoshima, Junichi
    [J]. NATURE REVIEWS CARDIOLOGY, 2018, 15 (07) : 387 - 407
  • [2] Mechanisms of physiological and pathological cardiac hypertrophy
    Michinari Nakamura
    Junichi Sadoshima
    [J]. Nature Reviews Cardiology, 2018, 15 : 387 - 407
  • [3] IS DYSTROPHIN ABSENCE IMPLICATED IN THE TRANSITION FROM PHYSIOLOGICAL TO PATHOLOGICAL CARDIAC HYPERTROPHY?
    Prado, C.
    Blefari, V.
    Oliveira, D.
    Silva, C. A.
    Fazan, R.
    Salgado, H. C.
    Rossi, M. A.
    [J]. HEART, 2013, 99 : A132 - A132
  • [4] Are adherens junctions implicated in the transition from physiological to pathological cardiac hypertrophy?
    Prado, Cibele M.
    Blefari, Valdecir
    Santos, Daniele O.
    Malvestio, Lygia M. M.
    Pedro, Rubens F.
    Rossi, Marcos M.
    [J]. FASEB JOURNAL, 2013, 27
  • [5] Physiological and pathological cardiac hypertrophy
    Shimizu, Ippei
    Minamino, Tohru
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2016, 97 : 245 - 262
  • [6] Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges
    Julia Ritterhoff
    Rong Tian
    [J]. Nature Reviews Cardiology, 2023, 20 : 812 - 829
  • [7] Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges
    Ritterhoff, Julia
    Tian, Rong
    [J]. NATURE REVIEWS CARDIOLOGY, 2023, 20 (12) : 812 - 829
  • [8] Resveratrol prevents pathological but not physiological cardiac hypertrophy
    Vernon W. Dolinsky
    Carrie-Lynn M. Soltys
    Kyle J. Rogan
    Anita Y. M. Chan
    Jeevan Nagendran
    Shaohua Wang
    Jason R. B. Dyck
    [J]. Journal of Molecular Medicine, 2015, 93 : 413 - 425
  • [9] Resveratrol prevents pathological but not physiological cardiac hypertrophy
    Dolinsky, Vernon W.
    Soltys, Carrie-Lynn M.
    Rogan, Kyle J.
    Chan, Anita Y. M.
    Nagendran, Jeevan
    Wang, Shaohua
    Dyck, Jason R. B.
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2015, 93 (04): : 413 - 425
  • [10] Pathological vs. physiological cardiac hypertrophy
    Kavazis, Andreas N.
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2015, 593 (17): : 3767 - 3767